Goldman SachsGSDON'T BUYMar 12, 2013Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
Has been a well managed company for a long time and it is in the right group. Have traditionally traded at fairly high prices because they had chunky earnings. The one thing he doesn’t like about them is that they are so tied to trading and investment banking. He would prefer something a little more integrated such as Citigroup (C-N). (Also see Top Picks.)